Publications scientifiques

Depuis le 05/01/2026
  1. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet E, Le Jeunne C.
    Therapie. 2025
  2. Impact of Regulatory Events on JAK Inhibitor Prescribing in Rheumatoid Arthritis: Insights from the French MAJIK Registry.
    Truchetet ME, Prati C, Thevenot P, Bologna C, Alegria GC, Daien CI, Cornec D, Dernis E, Fautrel B, Pariente A, Roux C, Salmon JH, Sellam J, Hucteau E, Bezin J, Avouac J.
    Joint Bone Spine. 2025
  3. The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine.
    Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, Pariente A, Raschi E.
    Clin Pharmacol Ther. 2025
  4. Clinical and toxicological epidemiology of intoxications by new psychoactive substances in Reunion Island.
    Maillot A, Guyon J, Ma-Tsi-Leong M, Berly L, Weisse F, Mahé A, Roux GL, Nativel F, Daveluy A, Puech B, Marteau A, Leroy M, Plé O, Maillard O, Bastard S, Mete D.
    Int J Emerg Med. 2025
  5. Effectiveness of antihypertensive drugs for secondary prevention of ischaemic stroke: a nationwide historic cohort study.
    Perrier J, Gabet A, Olié V, Pariente A, Tzourio C, Bezin J.
    BMJ Open. 2025
  6. Impact of Liquid Sublingual Immunotherapy on Health Care Resource Use in Allergic Rhinitis and Asthma in the Real-world EfficAPSI Study.
    Devillier P, Demoly P, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Molimard M.
    J Investig Allergol Clin Immunol. 2025
  7. Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer.
    Singier A, Jarne Munoz A, Maumus-Robert S, Bérard X, Pariente A, Bezin J, Kempf E, Noize P.
    JAMA Netw Open. 2025
  8. Moving towards COPD control: Lessons, challenges, and the role of CONDOR, a new French respiratory research network.
    Ribeiro-Baptista B, Girodet PO, Le Rouzic O, Zysman M, Roche N, Regard L.
    Respir Med Res. 2025
  9. Sex Differences in the Use and Discontinuation of Recommended Drugs in Secondary Ischemic Stroke Prevention: A Regional Registry-Based Analysis.
    Perrier J, Domecq S, Lesaine E, Gilbert F, Saillour-Glenisson F, Rouanet F, Bezin J.
    J Womens Health (Larchmt). 2025
  10. How synthetic cannabinoid user profiles and consumption patterns can affect wastewater-based epidemiology.
    Devault DA, Peyré A, Cottereau V, Pleignet E, Daveluy A.
    Environ Sci Pollut Res Int. 2025
  11. Pharmacoepidemiology as the delicate science of constructing robust plausibility where there is no certainty: the case for hypertension in young adults.
    Pariente A.
    Eur Heart J. 2025
  12. Correction: Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study.
    Laurent E, Godillon L, Tassi MF, Marcollet P, Chassaing S, Decomis M, Bezin J, Laure C, Angoulvant D, Range G, Grammatico-Guillon L.
    Front Cardiovasc Med. 2025
  13. Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2.
    Lafay-Chebassier C, Girodet PO, Laine F, Allain JS, Pickering G, Latreille M, Demina A, Chevassus H, Ingrand I, Tartour E, Benhamouda N, Fraisse ML, Chamitava L, Plétan Y, Balland J, Donazzolo Y, Lafont B.
    Nicotine Tob Res. 2025
  14. Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.
    Dari L, Beradid S, Constans J, Pariente A, Renoux C.
    Eur Heart J Cardiovasc Pharmacother. 2025
  15. Appropriateness of oxycodone use for acute pain in surgical and obstetric departments using a clinical data warehouse.
    Xuereb F, Trin K, Griffier R, Salvo F, Frasca M, Noize P, Bezin J, Pariente A.
    Br J Clin Pharmacol. 2026
  16. FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception.
    Raschi E, Cutroneo P, Salvo F, Tuccori M, Khouri C.
    Clin Pharmacol Ther. 2025
  17. Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study.
    Néant N, Lê MP, Bouchet S, Lagoutte-Renosi J, Grégoire M, Parant F, Venisse N, Lalanne S, Lemaitre F, Muret P, Renou Q, Destere A, Gandia P, Flandre P, Peytavin G, Solas C; ANRS-MIE-CARLAPOP Study Group.
    Clin Infect Dis. 2025
  18. Development and Validation of a LC-MS/MS Method for Ripretinib and Its Metabolite: Example of a Journey From Laboratory Bench to Routine Application With a Greenness Assessment.
    Rakotovao C, Sharanek A, Burban A, Gueroue P, Bouchet S, Bouguéon G, Ducint D, Molimard M, Italiano A, Djabarouti S, Guyon J.
    Biomed Chromatogr. 2025
  19. Oncologists' knowledge, practices and ethical opinions about therapeutic misconception: a French national survey.
    Haaser T, Clair S, Marty S, Berdai D, Hoarau H, Saux MC, Dreyfuss D, Maternowski PJ.
    BMC Med Ethics. 2025
  20. Experimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studies.
    Swierczynski G, Guyon J, Molimard M, Garrigou A, Baldi I, Verdun-Esquer C, Villa A, Canal-Raffin M.
    J Hazard Mater. 2025